RAF1 and glioblastoma: In a recent study investigating the impact of the combination of hsa-miR- 34a- 5p and temozolomide on glioblastoma, hsa-miR- 34a- 5p was shown to potentiate the therapeutic efficacy of temozolomide by suppressing RAF1 in the MAPK pathway, inhibiting cell viability, migration and proliferation and increasing apoptosis in glioblastoma multiforme (Shadbad et al. 2024).